A-01 Registration Tuesday 14:00-18:00 |
A-02 Opening ceremony and welcome reception Tuesday 18:00-20:00 |
A-03 Registration Wednesday 08:00-08:40 |
A-04 Welcome and introduction Wednesday 08:40-08:55 |
A-05 Alexander Staab In Memoriam Hans Schaefer Wednesday 08:55-09:00 |
A-06 Joachim Grevel Panel Discussion: Modelling and Simulation and the Regulatory Process Wednesday 09:00-10:15 |
A-07 Coffee break, poster and software session I: posters in Group I (with poster numbers starting with I-) are accompanied by their presenter Wednesday 10:15-11:45 |
A-08 Bruno Bieth Model-based analyses for pivotal decisions, with an application to equivalence testing for biosimilars Wednesday 11:45-12:05 |
A-09 Sylvain Goutelle A unified in vivo modeling approach for quantitative prediction of the impact of gene polymorphism and drug interactions on drug exposure Wednesday 12:05-12:25 |
A-10 France Mentré Launch of the new journal 'CPT: Pharmacometrics & Systems Pharmacology' Wednesday 12:25-12:30 |
A-11 Nick Holford The International Society of Pharmacometrics Wednesday 12:30-12:35 |
A-12 Kyungsoo Park The World Conference on Pharmacometrics (WCoP) Wednesday 12:35-12:40 |
A-13 Lunch Wednesday 12:40-14:05 |
A-15 Jakob Ribbing Literature Model for FEV1 in COPD Trials – Separating the Dynamic Components of Placebo Effect, Disease Progression and Interacting Drug Effects Wednesday 14:55-15:15 |
A-16 Tea break, poster and software session II: posters in Group II (with poster numbers starting with II-) are accompanied by their presenter Wednesday 15:15-16:45 |
A-17 Thomas Eissing A physiologically-based PK/PD model to capture population variability for diabetes research and automatic blood glucose control Wednesday 16:45-17:05 |
A-18 Maria Kjellsson Predicting late-phase outcome from early-phase findings using a Model-Based Approach – Application to Type 2 Diabetes Mellitus Wednesday 17:05-17:25 |
A-19 Franziska Schädeli Stark Semi-physiologic population PKPD model characterizing the effect of bitopertin (RG1678) glycine reuptake inhibitor on hemoglobin turnover in humans Wednesday 17:25-17:45 |
A-20 James Yates Applying mechanistic pharmacokinetic-pharmacodynamic models (PKPD) to describe the growth and inhibition of xenograft tumours in rats and mice by targeted anti-cancer agents. Thursday 08:45-09:05 |
A-21 Ben-Fillippo Krippendorff Relationship between the dose of therapeutic antibodies and the inhibition of cytoplasmic and nuclear growth factor signalling Thursday 09:05-09:25 |
A-22 Mélanie Wilbaux Population K-PD joint modeling of tumor size and CA 125 kinetics after chemotherapy in relapsed ovarian cancer (ROC) patients Thursday 09:25-09:45 |
A-23 Ekaterina Gibiansky PK/PD modeling and optimization of eltrombopag dose and regimen for treatment of chemotherapy-induced thrombocytopenia (CIT) in cancer patients Thursday 09:45-10:05 |
A-24 Coffee break, poster and software session III: posters in Group III (with poster numbers starting with III-) are accompanied by their presenter Thursday 10:05-11:35 |
A-25 Thomas Dorlo Translational pharmacokinetic modelling and simulation for the assessment of duration of contraceptive cover after use of miltefosine for the treatment of visceral leishmaniasis Thursday 11:35-12:00 |
A-26 Sebastian Ueckert Application of Item Response Theory to ADAS-cog Scores Modelling in Alzheimer’s Disease Thursday 12:00-12:25 |
A-27 Presentation of Lewis Sheiner student session awards Thursday 12:25-12:30 |
A-28 Lunch Thursday 12:30-14:00 |
A-29 Mats Karlsson Introduction to Markov modelling Thursday 14:00-14:40 |
A-30 Oliver Ackaert A hidden Markov model to assess drug-induced sleep fragmentation Thursday 14:40-15:00 |
A-31 Tea break, poster and software session IV: posters in Group IV (with poster numbers starting with IV-) are accompanied by their presenter Thursday 15:00-16:30 |
A-32 Chee Ng Novel Hybrid Artificial Neural Network-Nonlinear Mixed Effect Model Modeling Approach for Population Data Analysis in Model-based Drug Development Thursday 16:30-16:50 |
A-33 William Denney N-dimensional Likelihood Profiling: An Efficient Alternative to Bootstrap Thursday 16:50-17:10 |
A-34 Gilbert Koch Modeling of delayed phenomena in PKPD by delay differential equations of lifespan type Thursday 17:10-17:30 |
A-35 Social event Thursday 20:00 |
A-36 Aris Dokoumetzidis Lumping of compartments Friday 09:00-09:35 |
A-37 Jin Jin Model-Based Meta-Analysis for the Efficacy and Safety of Paclitaxel in Cancer Patients Friday 09:35-09:55 |
A-38 Yasunori Aoki A practical algorithm for practical parameter identifiability analysis Friday 09:55-10:15 |
A-39 Preview of PAGE2013 Friday 10:15-10:25 |
A-40 Coffee break Friday 10:25-10:55 |
A-41 Anne-Gaelle Dosne A strategy for residual error modeling incorporating both scedasticity of variance and distribution shape Friday 10:55-11:15 |
A-42 Ron Keizer Extended NPDE diagnostics for the between-subject variability and residual error model Friday 11:15-11:35 |
A-43 Camille Vong Handling Below Limit of Quantification Data in Optimal Trial Design Friday 11:35-11:55 |
A-44 France Mentré Survey on the current use of optimal design approaches and the developments needed in adaptive optimal design for model based analysis performed amongst DDMoRe’s EFPIA members Friday 11:55-12:15 |
A-45 Closing remarks Friday 12:15-12:25 |
A-46 Audience input for potential PAGE2013 topics Friday 12:25-12:40 |
I-01 Robert Leary QRPEM, A Quasi-Random Parametric EM Method Wednesday 10:15-11:45 |
I-02 Donghwan Lee Quantitative Analysis of Reflux Episodes in Gastroesophageal Reflux Disease (GERD) Wednesday 10:15-11:45 |
I-03 Eun-Kyung Lee Various validation methods to check the estimation methods with stochastic sampling approach Wednesday 10:15-11:45 |
I-04 Joomi Lee Population Pharmacokinetics of Sumatriptan in Healthy Korean Male Subjects Wednesday 10:15-11:45 |
I-05 Annabelle Lemenuel Diot Identification of a dual mechanism of action (MoA) for Danoprevir (DNV), a protease inhibitor currently in phase 2, using a mechanistic viral kinetic model Wednesday 10:15-11:45 |
I-06 Sergei Leonov Optimal design of population pharmacokinetic/pharmacodynamic studies Wednesday 10:15-11:45 |
I-07 Claire Li Clinical trial simulations of the anticancer agents- abiraterone and nilotinib Wednesday 10:15-11:45 |
I-08 Earvin Liang Clinical Trial Design Optimization: A Pharmacokinetic Sampling Plan for a Phase 3 Clinical Trial in Mild Alzheimer Disease Patients Wednesday 10:15-11:45 |
I-09 Floriane Lignet Computational Model of In Vitro Breast Cancer Cells Spheroid-Formation Wednesday 10:15-11:45 |
I-10 Lars Lindbom Addressing variability and uncertainty in pooled pre-clinical data improved the quality of compound selection of a gamma secretase modulator in Alzheimer’s Disease Wednesday 10:15-11:45 |
I-11 Rocio Lledo Dose escalation studies for mAb: prior distributions selection and software comparison Wednesday 10:15-11:45 |
I-13 Gaohua Lu Application of the Simcyp PBPK/PD model to Simulate PK and PD of Nifedipine in Japanese Populations Wednesday 10:15-11:45 |
I-14 James Lu Refining the mechanism of CETP mediated lipid transfer in a stochastic model of lipoprotein metabolism and kinetics (LMK model) Wednesday 10:15-11:45 |
I-15 Peiming Ma Organization of Target-Mediated Disposition (TMD) Models including Michaelis-Menten (MM), rapid-binding (RB), and quasi-steady-state (Qss) models Wednesday 10:15-11:45 |
I-16 Arianna Madrid Aispuro A Systematic Approach to PKPD Model Development to describe Sleep Effects of Compounds with Different Mechanisms of Action Using Semi-Mechanistic Markov Chain Models Wednesday 10:15-11:45 |
I-17 Victor Mangas-Sanjuan Three Compartment Model To Describe Atipical Permeability Profiles In CACO-2 Cells Wednesday 10:15-11:45 |
I-18 Mathilde Marchand How to support a definitive bioequivalence study design using modeling and simulation Wednesday 10:15-11:45 |
I-19 John Maringwa Model-based meta-analysis of summary clinical outcome data in idiopathic pulmonary fibrosis (IPF) Wednesday 10:15-11:45 |
I-20 Eleonora Marostica Second order Markov modelling of HAMD responses in depression trials Wednesday 10:15-11:45 |
I-21 Amelie Marsot Thiopental and esomeprazole in critically ill patients: Drug interaction. Wednesday 10:15-11:45 |
I-22 Silvia Illamola Population pharmacokinetics of amikacin in newborns Wednesday 10:15-11:45 |
I-23 Maria Matoses Osborne Development of a PBPK model for the anticancer drug Vivia009 and its main metabolite administered as a new delivery system in the Rat Wednesday 10:15-11:45 |
I-24 Veronese Mattia Optimal Experimental Design for receptor drug development with PET studies Wednesday 10:15-11:45 |
I-25 Christophe Meille Modified model of drug induced thrombocytopenia efficiently projects safe starting dose in human from preclinical data Wednesday 10:15-11:45 |
I-26 Sven Mensing Evaluation of the long-term decline of platelets following Navitoclax (ABT-263) administration in Cancer Patients with a semi-physiological pharmacodynamic model Wednesday 10:15-11:45 |
I-27 François Mercier A discussion on two approaches for indirect treatment comparisons based on public-domain metadata: The case of side-effects incidence Wednesday 10:15-11:45 |
I-28 Enrica Mezzalana A Target-Mediated Drug Disposition model to quantify the relationship between Anti-CD3 monoclonal antibody and CD3/TCR receptors in Patients with autoimmune diseases. Wednesday 10:15-11:45 |
I-29 Jonathan Mochel Using nonlinear mixed effects modeling to characterize the pharmacokinetics and pharmacodynamics of benazepril in dogs. Wednesday 10:15-11:45 |
I-30 Samer Mouksassi Equivalence of locally acting drugs based on pharmacodynamic data: development of a novel 1 step method and use of trial simulations to assess sources of variability and power definitive studies Wednesday 10:15-11:45 |
I-31 Ricardo Nalda-Molina Stochastic Simulations Assist to Improve a Poorly Designed Clinical Study for the CSF Pharmacokinetics of Doripenem Wednesday 10:15-11:45 |
I-32 Carmen Navarro Computer simulations of bioequivalence trials: drugs with sequential metabolism Wednesday 10:15-11:45 |
I-33 Michael Neely Non-Parametric Bayesian Fitting: A Novel Approach to Population Pharmacokinetic Modeling Wednesday 10:15-11:45 |
I-34 Thu Thuy Nguyen Modelling the impact of fecal ciprofloxacin concentrations on fecal counts of resistant Enterobacteriaceae in piglets treated with ciprofloxacin: towards new means to control the spread of resistance? Wednesday 10:15-11:45 |
I-35 Ronald Niebecker Modelling of Anti-Drug Antibodies Directed Against a Monoclonal Antibody Wednesday 10:15-11:45 |
I-36 Christoph Niederalt The use of physiologically-based pharmacokinetic modeling in the design of pH-dependent target binding antibodies Wednesday 10:15-11:45 |
I-37 Elisabet Nielsen Target Attainment Analysis to Evaluate Dosing Regimens of an Oral β-Lactam Antibioic Wednesday 10:15-11:45 |
I-38 Valerie Nock Comparison of three PK/PD models for glycated haemoglobin in diabetes type 2 patients treated with lixisenatide Wednesday 10:15-11:45 |
I-39 Yookhwan Noh Bioequivalence evaluation using population modeling method Wednesday 10:15-11:45 |
I-40 Joakim Nyberg The robustness of global optimal designs Wednesday 10:15-11:45 |
I-41 Kayode Ogungbenro A semi-mechanistic gastric emptying model for double peaks in pharmacokinetics using LDOPA data Wednesday 10:15-11:45 |
I-42 Katie Owens The Pharmacokinetic Profile of Intravenous Paracetamol in Adult Patients Undergoing Major Surgery: A Population Analysis Wednesday 10:15-11:45 |
I-43 Sung Min Park Population pharmacokinetics of S-amlodipine in healthy Korean male subjects Wednesday 10:15-11:45 |
I-45 Zinnia Parra-Guillen Tumour Growth Modelling In Immunotherapy Wednesday 10:15-11:45 |
I-46 Mélanie Pastor Modeling of the effect of G-CSF in limiting the neutropenic toxicity of carboplatin Wednesday 10:15-11:45 |
I-47 Pavan Vajjah Prediction of serum and cerebrospinal fluid concentrations of carbamazepine: An application of parameter estimation and the permeability limited 4-compartment brain model in Simcyp® Wednesday 10:15-11:45 |
I-48 Kirill Peskov Mechanistic modeling approach relating human gut microbial community to physiologically-relevant biomarkers Wednesday 10:15-11:45 |
I-49 Klas Petersson Simultaneous modeling of prolactin data following administration of seven D2–receptor antagonists in rats; Model-based in vitro – rat – human scaling Wednesday 10:15-11:45 |
I-50 Chiara Piana Non-adherence to antiretroviral combination therapy in HIV-infected children Wednesday 10:15-11:45 |
I-51 Sabine Pilari Mathematical Model of Homeostasis of Endogenous Hormones Following Hormone Replacement Therapy Wednesday 10:15-11:45 |
I-52 Venkatesh Pilla Reddy Translational PKPD modeling in schizophrenia: linking receptor occupancy of antipsychotics to efficacy and safety Wednesday 10:15-11:45 |
I-53 Elodie Plan Bayesian Joint Modeling of Bone Mineral Density and Repeated Time-To-Fracture Event for Multiscale Bone Systems Model Extension Wednesday 10:15-11:45 |
I-54 Bart Ploeger Investigation of a Data Transformation Procedure to Improve Identifiability of Efficacy and Potency: Application to Continuous Elevated Plus-Maze Data in Rats Wednesday 10:15-11:45 |
I-55 Arnaud Quelin How Anti-cancer Targeted Therapies Used in Combination Interact? Analysis with a Semi-mechanistic Model of Minimal Signalling Networks Wednesday 10:15-11:45 |
I-56 Christian Hove Claussen Pharmacokinetics of concentrated insulin mixtures: a biosimulation approach Wednesday 10:15-11:45 |
I-57 Dinko Rekic External validation of the bilirubin-atazanavir nomogram for assessment of atazanavir plasma exposure in HIV-1 infected patients Wednesday 10:15-11:45 |
I-58 Sylvie Retout Prediction of occurrence of thrombocytopenia to select Phase 1b dose and dosing regimen for a selective inhibitor of p53-MDM2 in patients with solid tumors Wednesday 10:15-11:45 |
I-59 Benjamin Ribba A model for low-grade glioma tumor growth and response to chemotherapy and radiotherapy Wednesday 10:15-11:45 |
I-60 Nikita Rodichenko Multimodal Physiologically-Based Modelling and Analysis of Kinetics of Drug-Delivery with Modular Nanotransporters (MNT) Wednesday 10:15-11:45 |
I-61 Rikke Meldgaard Røge Integrated model of glucose homeostasis including the effect of exogenous insulin Wednesday 10:15-11:45 |
I-62 Hyerang Roh Quantitative assessment of drug response in male patients with severe nocturia receiving a combined medication of solifenacin and tamsulosin Wednesday 10:15-11:45 |
I-63 Rachel Rose Prediction of the Hypnotic Effects of Zolpidem by Extrapolation of a Mechanism-Based PKPD Model Developed for Triazolam in Healthy Volunteers. Wednesday 10:15-11:45 |
I-64 Roel Straetemans Pharmacokinetic/Pharmacodynamic Simulations Of The vWF Targeting Nanobody® ALX-0081 In Pediatric Patients With TTP Wednesday 10:15-11:45 |
I-65 Amit Roy Characterization of the Occurrence, Severity, and Duration of Immune-Related Adverse Events (irAEs) in Advanced Melanoma Patients Treated with Ipilimumab Wednesday 10:15-11:45 |
I-66 Hauke Ruehs Integrated PK/PD model for oxaliplatin in different human matrices Wednesday 10:15-11:45 |
I-67 Alberto Russu A new, second-order indirect model of depression time course Wednesday 10:15-11:45 |
I-68 Vargo Ryan Comparator based dose-response model prediction of clinical irrelevance following near miss bioequivalence results for Cmax Wednesday 10:15-11:45 |
I-69 Yu-Yuan Chiu Dose-Response Model of Lurasidone Treatment in Schizophrenia Wednesday 10:15-11:45 |
II-01 Teijo Saari Significant changes in pharmacokinetics of sufentanil during target controlled infusion of sufentanil for cardiac anaesthesia. Wednesday 15:10-16:40 |
II-02 Muhammad Waqas Sadiq Oxymorphone PKPD relationship and blood-brain barrier transport studied with microdialysis Wednesday 15:10-16:40 |
II-03 Mark Sale Identification of optimal NONMEM models using a multi-objective genetic algorithm. Wednesday 15:10-16:40 |
II-04 Nikolaos Tsamandouras Mapping in vitro and in vivo derived CYP3A ontogeny function: A critical comparison between various ontogeny models Wednesday 15:10-16:40 |
II-05 Maria Luisa Sardu Biomarker-driven Models of Tumour Growth Inhibition in preclinical animal studies Wednesday 15:10-16:40 |
II-06 Andre Schäftlein Microdialysate-corrected mid-interval model versus microdialysate-based integral model - Population pharmacokinetics of levofloxacin in peripheral tissues Wednesday 15:10-16:40 |
II-07 Emilie Schindler PKPD-Modeling of Standard Uptake Value (SUV) in Gastro-Intestinal Stromal Tumors (GIST) patients treated with sunitinib Wednesday 15:10-16:40 |
II-08 Alessandro Schipani Simultaneous population pharmacokinetic modelling of atazanavir and ritonavir in HIV-infected adults and assessment of different dose reduction strategies Wednesday 15:10-16:40 |
II-09 Rik Schoemaker Modelling and simulation of spontaneously reported adverse events after administration of lacosamide Wednesday 15:10-16:40 |
II-10 Bernard Sebastien Impact of delayed effect in Concentration-QT analyses. Wednesday 15:10-16:40 |
II-11 Eric Sherer Three case studies of pharmacokinetic model building using a multi-objective genetic algorithm Wednesday 15:10-16:40 |
II-12 Kwang-Hee Shin Population Pharmacokinetics and Pharmacodynamics of Escitalopram in Healthy Volunteers Wednesday 15:10-16:40 |
II-13 Satoshi Shoji Population Pharmacokinetics/Pharmacodynamics of Ampicillin/Sulbactam in Patients with Moderate or Severe Community-Acquired Pneumonia Wednesday 15:10-16:40 |
II-14 Hanna Silber Baumann Population pharmacokinetics of cyclosporine A in cats Wednesday 15:10-16:40 |
II-15 Monica Simeoni Estimation of Remifentanil Metabolic Ratio Using a Mixture Model Wednesday 15:10-16:40 |
II-16 Nicolas Simon A joint PK/PD-PD model of levodopa in patients with Parkinson's disease: Motor effect and Movement disorder Wednesday 15:10-16:40 |
II-17 Jean Smeets Development of a mechanistic based model for neonatal Fc receptor recycling to design human serum albumin mutants with extended half-lives Wednesday 15:10-16:40 |
II-18 Nelleke Snelder Quantification of Antidepressant and Sedative Effect of Two NMDA Channel Blockers, AZD6765 and Ketamine, in an Animal Model of Depression Using Count Data Wednesday 15:10-16:40 |
II-19 Alexander Solms Using Population PBPK Modelling to interpret Population PK results exemplified for Levofloxacin in Plasma and Interstitial Fluid Wednesday 15:10-16:40 |
II-20 Hankil Son Development of a longitudinal model to describe the QT-time course in healthy volunteers given placebo and moxifloxacin Wednesday 15:10-16:40 |
II-21 Alexandre Sostelly Dose and dose schedule optimization of anticancer drugs Wednesday 15:10-16:40 |
II-22 Alexander Staab A Model-based Meta-analysis Comparison of the Effects of Linagliptin and Sitagliptin on HbA1c Levels in Patients with Type 2 Diabetes Mellitus Wednesday 15:10-16:40 |
II-23 David Stepensky Inter-patient variability of local vs. systemic effects of TNF-α-neutralizing antibodies in rheumatoid arthritis Wednesday 15:10-16:40 |
II-24 Jasper Stevens Nonlinear mixed effects evaluation of Hamilton Depression Rating Score following combination treatment of presynaptic- and postsynaptic glutamate receptor inhibitors in bipolar depression patients Wednesday 15:10-16:40 |
II-25 Elisabet Størset Population pharmacokinetics of tacrolimus to aid individualized dosing in kidney transplant recipients Wednesday 15:10-16:40 |
II-26 Fran Stringer A Novel Pharmacodynamic Modeling Approach to Determine Long Term Disease Progression Rates in Japanese Type 2 Diabetes Patients: Pioglitazone vs. Conventional Therapy Wednesday 15:10-16:40 |
II-28 Herbert Struemper Target-mediated clearance of ofatumumab: a tale of different disease states Wednesday 15:10-16:40 |
II-29 Elin Svensson Linear approximation methods for fast evaluation of random effects models Wednesday 15:10-16:40 |
II-30 Stina Syvänen P-glycoprotein alterations at the blood-brain barrier influences [11C]flumazenil brain concentrations but does not interfere with estimation of GABAA receptor density in a rodent model of epilepsy Wednesday 15:10-16:40 |
II-31 Takeshi Tajima Mechanism-based assessment on the pharmacodynamics of neuromuscular relaxants and general consideration for receptor blockers Wednesday 15:10-16:40 |
II-32 Daniel Tatosian Strategic comparator modeling and simulation to optimize dose selection for a dose-range finding study Wednesday 15:10-16:40 |
II-33 David Ternant A model predicting expected infliximab serum concentrations using only dose and time since last infusion Wednesday 15:10-16:40 |
II-34 Nadia Terranova Modelling of protozoa dynamics and drug effects in a murine model of malaria infection Wednesday 15:10-16:40 |
II-35 Hoai-Thu Thai Residual-based bootstrap methods for estimating uncertainty of parameters in nonlinear mixed-effects models with heteroscedastic error Wednesday 15:10-16:40 |
II-36 Kirstin Thelen Dynamically simulating the effect of food on gastric emptying using a detailed physiological model for gastrointestinal transit and absorption Wednesday 15:10-16:40 |
II-37 Mirjam Trame Evaluating the Influence of Different Covariates on Enoxaparin Pharmacokinetics in Neonates, Infants and Children Wednesday 15:10-16:40 |
II-38 Kellie Turner Adapting a Target-mediated Drug Disposition (TMDD) Model to Account for Delayed tmax Following IV Infusion of a Monoclonal Antibody Wednesday 15:10-16:40 |
II-39 Wanchana Ungphakorn Development of Sparse Sampling Study of Oral Ciprofloxacin for Severely Malnourished Children Wednesday 15:10-16:40 |
II-40 Pyry Välitalo Optimal design for a population pharmacokinetic study of oxycodone in preterm neonates, neonates and infants Wednesday 15:10-16:40 |
II-41 Marta Valle Population pharmacokinetics of rupatadine in children 2-11 years of age with allergic rhinitis Wednesday 15:10-16:40 |
II-42 Sven van Dijkman Characterisation of response and disease progression in paediatric epilepsy Wednesday 15:10-16:40 |
II-43 Coen van Hasselt Model-based evaluation and optimization of cardiac monitoring protocols for adjuvant treatment of breast cancer with trastuzumab Wednesday 15:10-16:40 |
II-44 Charlotte van Kesteren Predictive performance of a busulfan pharmacokinetic-model in children and young adults from five international transplant centers: a study of varying doses, underlying diseases, ethnicities, body weights, ages and body mass indices Wednesday 15:10-16:40 |
II-45 Eline van Maanen A step-wise analysis of multiple biomarkers drives the development of a Semi-Mechanistic Comprehensive Model. Application to modulation of Amyloid-β. Wednesday 15:10-16:40 |
II-46 Nieves Velez de Mendizabal Discrete distribution models for relapsing-remitting dynamics observed in Multiple Sclerosis Wednesday 15:10-16:40 |
II-47 Anders Viberg Using modeling and simulation to evaluate placebo run-in for pain studies Wednesday 15:10-16:40 |
II-48 Marie Vigan Evaluation of estimation methods for repeated time to event models: application to analysis of bone events during treatment of Gaucher Disease. Wednesday 15:10-16:40 |
II-49 Nageshwar Budha Population Analysis of wet-AMD Disease Progression and The Therapeutic Effect of Ranibizumab Wednesday 15:10-16:40 |
II-50 Sandra Visser MModel-based meta analysis of -secretase inhibitor data; has A production inhibition been adequately tested as therapeutic approach in mild AD? Wednesday 15:10-16:40 |
II-51 Georgios Vlasakakis Landscape on technical and conceptual requirements in Drug/Disease Modelling & Simulation Wednesday 15:10-16:40 |
II-52 Max von Kleist PK-PD Modelling of the Reverse Transcriptase Inhibitor Tenofovir and Quantification of its Prophylactic Efficacy against HIV-1 Infection Wednesday 15:10-16:40 |
II-53 Carin Wallsten Quantification of the Drug Effect and Exploration of Mechanism of Action of Two NMDA Channel Blockers, AZD6765 and Ketamine, using Mouse EEG Data Wednesday 15:10-16:40 |
II-54 Bing Wang Population pharmacokinetics and pharmacodynamics of mavrilimumab in rheumatoid arthritis patients Wednesday 15:10-16:40 |
II-55 Chenguang Wang Scaling morphine across the human life-span using a bodyweight-dependent allometric exponent model Wednesday 15:10-16:40 |
II-56 Sebastian Weber Mixed effect modeling of neuronal cell differentiation kinetics from longitudinal phase-contrast imaging data Wednesday 15:10-16:40 |
II-57 Thomas Wendl A whole-body physiologically-based pharmacokinetic Model for ketoconazole in different species ready to be used to predict dynamic drug-drug-interactions Wednesday 15:10-16:40 |
II-58 Shelby Wilson The Enhancement of Tumor Vaccine Efficacy by Immunotherapy Wednesday 15:10-16:40 |
II-59 Gudrun Wuerthwein Population Pharmacokinetics of caspofungin in a phase II dose escalation study Wednesday 15:10-16:40 |
II-60 Wenyuan Xiong Pharmacokinetic interspecies extrapolation of a fully human mAb from animal to human Wednesday 15:10-16:40 |
II-61 Stefano Zamuner PK-PD modelling of aOSM in RA patient study including exploration of carrier protein effect. Wednesday 15:10-16:40 |
II-62 Stefan Zeiser Population PK Modeling of Dapivirine Released from Vaginal Rings Wednesday 15:10-16:40 |
II-63 Jianping Zhang Population Analysis of Tumor Growth Inhibition and Progression-Free Survival Following Lapatinib Treatment in Patients with Advanced/Metastatic Breast Cancer Wednesday 15:10-16:40 |
II-64 Chao Zhang Model-based evaluation of the pharmacokinetic differences between adults and children administered lopinavir and ritonavir in combination with rifampicin Wednesday 15:10-16:40 |
II-65 Wei Zhao Population pharmacokinetics and dosing optimization of vancomycin continuous infusion in neonates Wednesday 15:10-16:40 |
II-66 Kirill Zhudenkov Application of the SBTOOLBOX2 in drug discovery and development Wednesday 15:10-16:40 |
II-67 BELA PATEL Probability-Based Risk Assessment of QT Prolongation in Early Phase Drug Development Wednesday 15:10-16:40 |
II-68 Parviz Ghahramani Population Pharmacokinetic Model for Cariprazine and its Major Metabolites in Patients with Acute Exacerbation of Schizophrenia Wednesday 15:10-16:40 |
III-01 Khaled Abduljalil Predicting the Developmental PK/PD of Cyclosporine (CsA) in Paediatrics Thursday 10:05-11:35 |
III-02 Mona Alameddine Pragmatic Approach for Interpreting Antiretroviral Drug Concentrations Based on a Systematic Review of Population Pharmacokinetic Studies Thursday 10:05-11:35 |
III-03 Azucena Aldaz Capecitabine: a pharmacokinetic model derived from its clinical use Thursday 10:05-11:35 |
III-04 Oskar Alskär Using allometric scaling on an integrated glucose insulin model for humans to investigate anti-diabetics drug effects in rats. Thursday 10:05-11:35 |
III-05 Claire Ambery Application of population dose-response and dose frequency in respiratory Thursday 10:05-11:35 |
III-06 Orna Amir Mechanistic NSCLC vascular tumor model: insights to prognosis towards personalized medicine Thursday 10:05-11:35 |
III-07 Jacqueline Anderson PKPD modelling of human chlorpyrifos poisoning Thursday 10:05-11:35 |
III-08 Eduardo Asín-Prieto Population pharmacokinetics of piperacillin in critically ill patients undergoing continuous renal replacement therapies Thursday 10:05-11:35 |
III-09 Bengt Hamren Log likelihood profile intervals for ED50 Thursday 10:05-11:35 |
III-10 Daren Austin A closed-form solution set-point model of treatment response in multiple diseases Thursday 10:05-11:35 |
III-11 Nicolas Azzopardi Modelization of bevacizumab effect on number of episodes of epistaxis in Hereditary Haemorrhagic Telangiectasia (HHT) Thursday 10:05-11:35 |
III-12 Gaurav Bajaj Model-based analysis of disease progression in pancreatic cancer based on registry data collected from the Surveillance, Epidemiology, and End Result (SEER) database Thursday 10:05-11:35 |
III-13 Francesco Bellanti Deferiprone sampling optimisation in a pharmacokinetic bridging study including children with β-thalassaemia Thursday 10:05-11:35 |
III-14 Brendan Bender A multicompartmental population PK model elucidating the complex disposition of trastuzumab emtansine (T-DM1): an antibody-drug conjugate for the treatment of HER2-positive cancer Thursday 10:05-11:35 |
III-15 Margherita Bennetts Delta Method Application: Landmark Prediction and Confidence Interval for a Non-Linear Longitudinal Model Thursday 10:05-11:35 |
III-16 Aliénor Bergès Development of a mechanistic PK/PD model to guide dose selection of a combined treatment for systemic amyloidosis Thursday 10:05-11:35 |
III-17 Tarjinder Sahota A mechanistic PK/PD model to predict the pharmacological depletion of serum amyloid P component in healthy volunteers Thursday 10:05-11:35 |
III-18 Kirsten Bergmann Comparing a mechanistic with an empirical approach to assess resistance development of antibacterials in vitro. Thursday 10:05-11:35 |
III-19 Julie Bertrand Population Pharmacokinetic-Pharmacogenetic study of Efavirenz in combination with anti-TB treatment in HIV-Infected Cambodian Patients Thursday 10:05-11:35 |
III-20 Roberto Bizzotto Glucose Homeostasis Modeling: Improvement of the Insulin Action Component Thursday 10:05-11:35 |
III-21 Marcus Björnsson A population PK/PD model for bispectral index of the fast acting anesthetic AZD3043 in healthy volunteers Thursday 10:05-11:35 |
III-22 Michael Block Physiological modeling of inter-individual variability: Combining PBPK modeling and Markov-Chain-Monte-Carlo approaches Thursday 10:05-11:35 |
III-23 Michael Bolger GastroPlus PBPK/PD Model Applied to Estimating Dose for an Elderly Population in an Alzheimer’s Disease Clinical Trial Thursday 10:05-11:35 |
III-24 Irina Bondareva Population Pharmacokinetics of Phenytoin Estimated from Repeated Therapeutic Drug Monitoring (TDM) Data of Epileptic Patients Thursday 10:05-11:35 |
III-25 Emma Bostrom Modeling and Simulation of Pharmacokinetics and H3 Receptor Occupancy for Dose Setting in a Phase IIa Study Thursday 10:05-11:35 |
III-26 Salim Bouchene Whole Body Physiologically-Based Pharmacokinetic Model of Colistin and Colistimethate sodium in Critically Ill Patients Thursday 10:05-11:35 |
III-27 Marion Bouillon-Pichault Modeling of pain scores from a flexible titration study using an ordered categorical approaches Thursday 10:05-11:35 |
III-28 Frances Brightman Predicting in vivo drug response and synergistic combinations from three-dimensional tumour cell cultures Thursday 10:05-11:35 |
III-29 Margreke Brill Population pharmacokinetic model for cefazolin in serum and subcutaneous adipose tissue in morbidly obese and normal weight patients Thursday 10:05-11:35 |
III-30 Thierry Buclin Monitoring Blood Prostate-Specific Antigen (PSA) after Radical Prostatectomy Thursday 10:05-11:35 |
III-31 Núria Buil Bruna Modeling evaluation of different in vitro experimental designs to characterise antitumor drug effect Thursday 10:05-11:35 |
III-32 Theresa Cain A systems approach to predicting differences in pharmacological response to a CYP1A2 substrate, resulting from pharmacokinetic differences in non-smokers, passive smokers and heavy smokers Thursday 10:05-11:35 |
III-33 Sophie Callies Sensitivity analysis to help the assessment of variance: application to Target Mediated Drug Disposition (TMDD) PK/PD model describing the effect of a monoclonal antibody (mAb) on a circadian biomarker. Thursday 10:05-11:35 |
III-34 Yu-Jung Cha Population Pharmacokinetics of Etanercept in Healthy Korean Male Volunteers Thursday 10:05-11:35 |
III-35 Quentin Chalret du Rieu Semi-mechanistic thrombocytopenia model of a new histone deacetylase inhibitor (HDACi) in development, with a drug-induced apoptosis of megakaryocytes. Thursday 10:05-11:35 |
III-36 Pascal Chanu On the use of hemodynamics biomarkers to assess the benefit of high doses of sildenafil in some patients with pulmonary arterial hypertension (PAH) Thursday 10:05-11:35 |
III-37 Ayyappa Chaturvedula Development of population pharmacokinetic model for Tenofovir using sparsely sampled subject data Thursday 10:05-11:35 |
III-38 Chao Chen Quantifying the Effectiveness of Dose Personalisation by Simulation for a Drug with Moderate Pharmacokinetic Variability Thursday 10:05-11:35 |
III-39 Marylore Chenel In vitro – in vivo correlation by population approach applied to modified-release forms with double-peak absorption Thursday 10:05-11:35 |
III-40 S. Y. Amy Cheung An update on structural identifiability of parallel pharmacokinetic experiments viewed as constrained systems Thursday 10:05-11:35 |
III-42 Karina Blei Development and evaluation of dynamical whole body Physiologically-based Models of the Circulation and the Renin-Angiotensin-Aldosterone system Thursday 10:05-11:35 |
III-43 Laurent Claret Evaluation of Tumor-Size Response Metrics to Predict Survival and Progression Free Survival in First-Line Metastatic Colorectal Cancer Thursday 10:05-11:35 |
III-44 Francois Combes Prediction of precision of individual parameter estimates and of shrinkage via the Bayesian Fisher information matrix in non-linear mixed-effects models with application in pharmacokinetics Thursday 10:05-11:35 |
III-45 Emmanuelle Comets Dealing with BQL data in normalised prediction distribution errors: a new version of the npde library for R Thursday 10:05-11:35 |
III-46 Damien Cronier Population Pharmacokinetic Study of a New Humanized Anti-CD20 Monoclonal Antibody AME-133v (LY2469298) in Patients with Previously Treated Folicular Lymphoma. Thursday 10:05-11:35 |
III-47 Zeinab Daher Abdi Joint model for longitudinal exposure to mycophenolic acid and rejection survival data in the first year after renal transplantation Thursday 10:05-11:35 |
III-48 Elyes Dahmane The influence of CYP2D6 genetic polymorphism on tamoxifen and its active metabolite exposure in breast cancer patients: preliminary results from a prospective, open-label trial. Thursday 10:05-11:35 |
III-49 Adam Darwich Development and application of a mechanistic physiologically based pharmacokinetic model to assess oral drug bioavailability post bariatric surgery in morbidly obese patients Thursday 10:05-11:35 |
III-50 Ruben de Kanter The impact of using the well-stirred liver model in PBPK modelling for high-clearance compounds Thursday 10:05-11:35 |
III-51 Giuseppe De Nicolao PCA-based modelling in antidepressant trials: a pre-mechanistic approach Thursday 10:05-11:35 |
III-52 Ivan Demin Posterior predictive check to assess similarity of systemic exposure profiles of an inhaled drug product pre- and post- manufacturing modification. Thursday 10:05-11:35 |
III-53 Paolo Denti Population pharmacokinetics of ritonavir-boosted darunavir together with efavirenz in healthy volunteers Thursday 10:05-11:35 |
III-54 Kristin Dickschen Evaluation of CYP2D6 Phenotype-Guided Tamoxifen Dosing in European Female Breast Cancer Patients using a PBPK-Model Thursday 10:05-11:35 |
III-55 Christian Diestelhorst A Physiologically-Based Pharmacokinetic Model for Busulfan Thursday 10:05-11:35 |
III-56 Nassim Djebli Pharmacokinetic/pharmacodynamic (PK/PD) Analysis of Teriflunomide in Patients with Relapsing Forms of Multiple Sclerosis (RMS) Thursday 10:05-11:35 |
III-57 Jennifer Dong Assessment of Mechanism of Action and Drug Effects in Early Signal of Efficacy Trials Using Integrated Glucose-Insulin Modeling: A Simulation-Estimation Approach Thursday 10:05-11:35 |
III-58 Pinky Dua A Systems Pharmacology model of the nerve growth factor (NGF) pathway to aid drug discovery and development Thursday 10:05-11:35 |
III-59 Vivek Dua Multi-objective Optimal Control of Non-Viral Gene Delivery Thursday 10:05-11:35 |
III-60 Anne Dubois Joint modelling of the placebo response and the dropout mechanism using clinical data from a trial performed in patients suffering from major depressive disorder Thursday 10:05-11:35 |
III-61 Cyrielle Dumont Optimal two-stage design for a population pharmacokinetic study in children Thursday 10:05-11:35 |
III-62 Jeroen Elassaiss-Schaap Pharmacokinetic-Pharmacodynamic Modelling & Simulation of Org 52186, a V3 antagonist, in Support of a Challenge Agent Trial Design with dDAVP Thursday 10:05-11:35 |
III-63 Farkad Ezzet Power Calculation Based on Pharmacokinetic Sampling Designs of ELND005 in a Phase 3 Clinical Trial Design in Mild Alzheimer Disease Patients Thursday 10:05-11:35 |
III-64 Iñaki F. Trocóniz Exploratory analysis to evaluate the relevance of different mechanism involved in a bivariate response target mediated disposition model characterizing the IL12 – IFNγ relationship. Thursday 10:05-11:35 |
III-65 Christine Falcoz Population PKPD modeling of an anti-diabetic compound with a new mechanism of action in ob/ob mice to predict the human dose Thursday 10:05-11:35 |
III-66 Mathieu Felices Dose Regimen Assessement For Oral Fexinidazole Thursday 10:05-11:35 |
III-67 Gregory Ferl A mixed-effects simulation approach to quantifying the impact of missing pre-treatment baseline clinical DCE-MRI data on estimated population parameters Thursday 10:05-11:35 |
III-68 Eric Fernandez A database of PK-PD parameters and information for the modelling of anti-cancer drug regimen and combinations Thursday 10:05-11:35 |
III-69 Martin Fink Population pharmacokinetic analysis of robenacoxib in dogs with chronic osteoarthritis Thursday 10:05-11:35 |
IV-01 Nicolas Frances A translational threshold model to assess exposure-driven QTc changes Thursday 15:00-16:30 |
IV-02 Ben Francis Using Stochastic Control Methods and Pharmacokinetics to Individualise Drug Therapy: A Case Study with the Enzyme Inhibitor Imatinib. Thursday 15:00-16:30 |
IV-03 Chris Franklin Practical Implications of Ontology and Global Standards for Model-based Data Analysis Thursday 15:00-16:30 |
IV-04 Nicolas Frey Short- and Long-Term Effects of Tocilizumab on Neutrophil Counts in Pediatric Patients with Systemic Juvenile Idiopathic Arthritis Thursday 15:00-16:30 |
IV-05 Lena Friberg Myelosuppression as a Biomarker of Tumor Response in Docetaxel Treated Metastatic Breast Cancer Patients Thursday 15:00-16:30 |
IV-06 Anne-Kristina Mercier A time-to-event model for acute rejections in paediatric renal transplant recipients treated with ciclosporin A Thursday 15:00-16:30 |
IV-07 Ludivine Fronton Relevance of Endogenous IgG Binding to FcRn in PBPK Models of Therapeutic mAbs Thursday 15:00-16:30 |
IV-08 Aline Fuchs Benchmarking therapeutic drug monitoring software: A systematic evaluation of available computer tools Thursday 15:00-16:30 |
IV-09 Samira Garonzik Development of PK/PD Models to describe Pharmacokinetics and Biomarker Responses for Dovitinib (TKI258) Thursday 15:00-16:30 |
IV-10 Peter Gennemark Experimental design based on mechanistic mathematical modeling of body composition and energy turnover Thursday 15:00-16:30 |
IV-11 Cecile Gerard Determination of the most influential sources of variability of tacrolimus trough blood levels in adult liver transplant patients: a bottom-up approach Thursday 15:00-16:30 |
IV-12 Massimiliano Germani Population pharmacokinetic analysis in healthy volunteers treated with different oral formulations of riluzole. Thursday 15:00-16:30 |
IV-13 Leonid Gibiansky Monoclonal Antibody-Drug Conjugates (ADC): TMDD Equations, Approximations, and Identifiability of Model Parameters Thursday 15:00-16:30 |
IV-14 Bill Gillespie From Evidence Synthesis to Trial Optimization: The adsim Package for Model-based Simulation in Alzheimer's Disease Thursday 15:00-16:30 |
IV-15 Pascal Girard Simultaneous Ocular Adverse Event and Treatment Discontinuation Model of Pimasertib Thursday 15:00-16:30 |
IV-16 Sophie Glatt A population pharmacokinetic analysis and pharmacokinetic/adverse events analysis of a sodium channel blocker in healthy subjects. Thursday 15:00-16:30 |
IV-17 Martin Gnanamuthu Johnson Title: Pharmacokinetic-Pharmacodynamic Modeling of the relationship between D2 receptor occupancy and Catalepsy in Rats: Predicting Extrapyramidal Side Effects in Humans Thursday 15:00-16:30 |
IV-18 Daniel Gonzalez Population Pharmacokinetics of Two Volatile Markers Used for Assessment of Definitive Adherence Thursday 15:00-16:30 |
IV-19 Linus Görlitz Physiological modeling of interindividual variability: PBPK-NLME vs. compartimental modeling Thursday 15:00-16:30 |
IV-20 Nathalie Gosselin Simultaneous Optimization of Sampling Strategies for Parent and Metabolite Data Taking into Account a Body Weight Distribution: Applications to Paediatric Studies Thursday 15:00-16:30 |
IV-21 Verena Gotta Probability of achieving optimal molecular response to imatinib in chronic myeloid leukemia (CML) patients: Pharmacokinetic/Pharmacodynamic (PK/PD) relationships observed under field-conditions Thursday 15:00-16:30 |
IV-22 Navin Goyal Kinetic-Pharmaco Dynamic (K-PD) Modeling of a Novel Oral 5-Lipoxigenase Activating Protein (FLAP) Inhibitor for Asthma and its Comparison with a PK-PD Approach Thursday 15:00-16:30 |
IV-23 Iztok Grabnar Enterohepatic Recirculation of Free and Conjugated Silybin Following Administration of a Chewing Gum with Milk Thistle Extract Thursday 15:00-16:30 |
IV-24 Joachim Grevel Response type modelling and clinical trial simulation. Thursday 15:00-16:30 |
IV-25 Zheng Guan Population PK/PD modeling to compare cannabinoid receptor antagonists in the THC challenge test Thursday 15:00-16:30 |
IV-26 Ivelina Gueorguieva Development Of Integrated Pharmacokinetic/Pharmacodynamic (PK/PD) Model For The Novel TGF- β Inhibitor LY2157299 Monohydrate: Preclinical To Phase II Thursday 15:00-16:30 |
IV-27 Monia Guidi Population Pharmacokinetics of Risperidone and 9-hydroxy-risperidone in psychiatric patients. Thursday 15:00-16:30 |
IV-28 Emma Hansson PKPD Modeling of Predictors for Side Effects and Overall Survival in Patients with Gastro Intestinal Stromal Tumor Treated with Sunitinib Thursday 15:00-16:30 |
IV-29 Eva Hanze Comparison of longitudinal data analysis to end of treatment data analysis when evaluating precision in dose-exposure-response in neuropathic pain studies. Thursday 15:00-16:30 |
IV-30 Lutz Harnisch Determining the Pharmacokinetic (PK) Profile of Sildenafil in One Month to One Year Old Pediatric Pulmonary Arterial Hypertension (PAH) Patients Using Interpolation of Two Population Pharmacokinetic Models of Sildenafil in PPHN population (3 to 10 Days Old) and in Pediatric PAH population (1 to 17 Years Old) Thursday 15:00-16:30 |
IV-31 Tomi Hendrayana Population pharmacokinetic (PK) model for fluorouracil (5-FU) accounting for irregularities in infusion rate Thursday 15:00-16:30 |
IV-32 Emilie Hénin A latent-variable model for Sorafenib-induced Hand-Foot Syndrome (HFS) in non-selected patients to predict toxicity kinetics according to sorafenib administrations Thursday 15:00-16:30 |
IV-33 Stefanie Hennig Pharmacokinetics of tobramycin do not differ in patients with and without cystic fibrosis Thursday 15:00-16:30 |
IV-34 Sarapee Hirankarn Pharmacokinetics Of High-Dose Methotrexate In Children With Cancer: A Mechanism Based Evalution Of Clearance Prediction Thursday 15:00-16:30 |
IV-35 Richard Höglund A population pharmacokinetic model of piperaquine in pregnant and non-pregnant women with uncomplicated P.falciparum malaria Thursday 15:00-16:30 |
IV-36 Nick Holford What is the between cycle variability in methotrexate clearance? Thursday 15:00-16:30 |
IV-37 Andrew Hooker The Kaplan-Meier Mean Covariate plot (KMMC): a new diagnostic for covariates in time-to-event models. Thursday 15:00-16:30 |
IV-38 Daniel Hovdal A mechanism-based population model for estimation of system parameters, vehicle effects and drug-induced body weight changes in diet induced obesity mice Thursday 15:00-16:30 |
IV-39 Xiao Hu Comparison of Tolerance Models for Neopterin Elevation Following Interferon beta-1a or PEGylated Interferon beta-1a treatment in Rhesus Monkeys Thursday 15:00-16:30 |
IV-40 An Hyungmi The Modified Bland-Altman Method to Measure Agreement with Repeated Measures Data using Random Effects Model Thursday 15:00-16:30 |
IV-41 Laura Iavarone A population PK model combined with PK/PD model for analysis of headache in clinical trials Thursday 15:00-16:30 |
IV-42 Vijay Ivaturi Individual Observation-Shrinkage Scaling of Residuals in a Generalized Least Square Type of Estimation in NONMEM Thursday 15:00-16:30 |
IV-43 Masoud Jamei Model-Based Prediction of Domperidone and Ketoconazole Interaction and its Impact on QTc Prolongation Thursday 15:00-16:30 |
IV-44 Candice Jamois Pharmacokinetic-Receptor Occupancy Modeling to support Phase 2 Dose Selection Thursday 15:00-16:30 |
IV-45 Alvaro Janda Optimization of pharmacokinetics and pharmacodynamics profiles by optimal control methods. Application to a triptorelin-testosterone PD model. Thursday 15:00-16:30 |
IV-46 Juliette Janson Population PKPD Modeling of BACE1 Inhibitor-Induced Reduction in Aβ Levels in vivo. Thursday 15:00-16:30 |
IV-47 Roger Jelliffe An Improved Population Model Prior for Nonparametric Sequential Interacting Multiple Model (IMM) Bayesian Analysis. Thursday 15:00-16:30 |
IV-48 Lee Jongtae Population pharmacokinetic analysis of colistin in burn patients Thursday 15:00-16:30 |
IV-49 Amita Joshi A physiologically-based pharmacokinetic (PBPK) approach to evaluate differences in pharmacokinetics between healthy subjects and cancer patients Thursday 15:00-16:30 |
IV-50 Matts Kågedal Improved dose selection for PET occupancy studies Thursday 15:00-16:30 |
IV-51 Friederike Kanefendt Modeling Sunitinib and Biomarker Response as potential Predictors of Time to Progression in Patients with Metastatic Colorectal Cancer Thursday 15:00-16:30 |
IV-52 Helene Karcher Therapeutic drug monitoring : modeling to assess risk and benefit for a novel drug used in combination Thursday 15:00-16:30 |
IV-53 Tatiana Karelina Kinetic Model of Amyloid Beta Distribution and Allometric Scaling from Mouse to Monkey and Human Thursday 15:00-16:30 |
IV-54 Mats Karlsson A full model approach based on the covariance matrix of parameters and covariates Thursday 15:00-16:30 |
IV-55 Nastya Kassir A Modelling and Simulations Framework to Optimize Paediatric Studies and Facilitate Decision-Making Thursday 15:00-16:30 |
IV-56 Takayuki Katsube Characterization of Stepwise Covariate Model Building Combined with Cross-Validation Thursday 15:00-16:30 |
IV-57 David Khan In silico predictions of in vitro growth competition experiments between wild type and resistant mutants of E. coli MG1655 exposed to ciprofloxacin Thursday 15:00-16:30 |
IV-58 Frank Kloprogge Population pharmacokinetics of lumefantrine in pregnant and non-pregnant women with uncomplicated Plasmodium falciparum malaria in Uganda Thursday 15:00-16:30 |
IV-59 Magdalena Kozielska Sensitivity of individual items of the Positive and Negative Syndrome Scale (PANSS) and items subgroups to differentiate between placebo and drug treatment in schizophrenia Thursday 15:00-16:30 |
IV-60 Elke Krekels Top-Down Modeling Meets Bottom-Up Modeling: The Physiological and Physicochemical Basis for the Ontogeny of UGT2B7-Mediated Drug Glucuronidation. Thursday 15:00-16:30 |
IV-61 Anders Kristoffersson Robust optimal design of ciprofloxacin time-kill curve experiments with respect to autocorrelation Thursday 15:00-16:30 |
IV-62 Wojciech Krzyzanski Methods of Solving Rapid Binding Target-Mediated Drug Disposition Model for Two Drugs Competing for the Same Receptor Thursday 15:00-16:30 |
IV-63 Steve Kuan Population Pharmacokinetic (PK) Modelling of Bortezomib After Bolus Intravenous Injection in Cancer Patients Thursday 15:00-16:30 |
IV-64 Brigitte Lacroix A single population pharmacokinetic model for oral levetiracetam in various populations – dose investigation for Japanese children Thursday 15:00-16:30 |
IV-65 Celine M. Laffont Application of a new method for multivariate analysis of longitudinal ordinal data testing robenacoxib in canine osteoarthritis Thursday 15:00-16:30 |
IV-66 Cédric Laouenan Modeling hepatitis C viral kinetics to compare antiviral potencies of two protease inhibitors: a simulation study under real conditions of use Thursday 15:00-16:30 |
IV-67 Anna Largajolli Visual Predictive Check (VPC) in models with forcing functions Thursday 15:00-16:30 |
IV-68 Christian Laveille Use of an exposure-response model for lacosamide in adults with partial onset seizures to analyze preliminary data from a pediatric trial Thursday 15:00-16:30 |
IV-69 Marc Lavielle On the use of stochastic differential mixed effects models for modeling inter occasion variability. Models and methods Thursday 15:00-16:30 |
S-01 Roger Jelliffe The MM-USCPACK Pmetrics research software for nonparametric population PK/PD modeling, and the RightDose clinical software for individualizing maximally precise dosage regimens. During entire meeting |
S-02 Coen van Hasselt Pirana: The flexible modeling environment for NONMEM During entire meeting |